Search research articles
Contact Us
Filters
Showing results (101-110 of 183) with videos related to
Page
of 19
Sort By:
BMC Cancer
|
June 26, 2019
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
BMC Cancer
|
June 1, 2019
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
Breast Cancer Research and Treatment
|
March 27, 2010
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H Barrios, Mei-Ching Liu, Soo Chin Lee, et al.
The Lancet. Oncology
|
November 4, 2021
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
Gustavo Werutsky, Carlos H Barrios, Andres F Cardona, et al.
Journal of Global Oncology
|
September 23, 2018
Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort
Vladmir C Cordeiro de Lima, Clarissa S Baldotto, Carlos H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2021
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993
L A Emens, S Adams, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2021
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L A Emens, S Adams, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2021
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993
L A Emens, S Adams, C H Barrios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 183) with videos related to
Sort By:
Page
of 19
BMC Cancer
|
June 26, 2019
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
BMC Cancer
|
June 1, 2019
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
Breast Cancer Research and Treatment
|
March 27, 2010
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H Barrios, Mei-Ching Liu, Soo Chin Lee, et al.
The Lancet. Oncology
|
November 4, 2021
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
Gustavo Werutsky, Carlos H Barrios, Andres F Cardona, et al.
Journal of Global Oncology
|
September 23, 2018
Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort
Vladmir C Cordeiro de Lima, Clarissa S Baldotto, Carlos H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2021
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993
L A Emens, S Adams, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2021
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L A Emens, S Adams, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2021
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993
L A Emens, S Adams, C H Barrios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Page
of 19